Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial

David Cella*, Viktor Grünwald, Paul Nathan, Justin Doan, Homa Dastani, Fiona Taylor, Bryan Bennett, Michael DeRosa, Scott Berry, Kristine Broglio, Elmer Berghorn, Robert J. Motzer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

158 Scopus citations

Fingerprint

Dive into the research topics of 'Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences